134 related articles for article (PubMed ID: 18822303)
1. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).
de la Flor R; Dawson LA
Neuropharmacology; 2009 Feb; 56(2):342-9. PubMed ID: 18822303
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
3. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release.
Ichikawa J; Chung YC; Dai J; Meltzer HY
Brain Res; 2005 Aug; 1052(1):56-62. PubMed ID: 16061211
[TBL] [Abstract][Full Text] [Related]
5. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex.
Huang M; Li Z; Ichikawa J; Dai J; Meltzer HY
Brain Res; 2006 Jul; 1099(1):44-55. PubMed ID: 16824491
[TBL] [Abstract][Full Text] [Related]
6. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA; Langmead CJ; Dada A; Watson JM; Wu Z; de la Flor R; Jones GA; Cluderay JE; Southam E; Murkitt GS; Hill MD; Jones DN; Davies CH; Hagan JJ; Smith PW
Eur J Pharmacol; 2010 Feb; 627(1-3):106-14. PubMed ID: 19879867
[TBL] [Abstract][Full Text] [Related]
8. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux.
Prus AJ; Huang M; Li Z; Dai J; Meltzer HY
Brain Res; 2007 Dec; 1184():354-64. PubMed ID: 17988654
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
Eltayb A; Wadenberg ML; Svensson TH
Biol Psychiatry; 2005 Aug; 58(4):337-43. PubMed ID: 16102547
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
Amargós-Bosch M; Adell A; Artigas F
J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
[TBL] [Abstract][Full Text] [Related]
11. New quinoline NK3 receptor antagonists with CNS activity.
Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
[TBL] [Abstract][Full Text] [Related]
12. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex.
Pira L; Mongeau R; Pani L
Eur J Pharmacol; 2004 Nov; 504(1-2):61-4. PubMed ID: 15507222
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex.
Li Z; Prus AJ; Dai J; Meltzer HY
J Pharmacol Exp Ther; 2009 Sep; 330(3):948-55. PubMed ID: 19491322
[TBL] [Abstract][Full Text] [Related]
14. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
Simmons MA; Sobotka-Briner CD; Medd AM
Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
[TBL] [Abstract][Full Text] [Related]
15. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex.
Sato M; Ago Y; Koda K; Nakamura S; Kawasaki T; Baba A; Matsuda T
Eur J Pharmacol; 2007 Mar; 559(2-3):155-60. PubMed ID: 17258195
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
[TBL] [Abstract][Full Text] [Related]
17. Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats.
Matsumoto M; Shikanai H; Togashi H; Izumi T; Kitta T; Hirata R; Yamaguchi T; Yoshioka M
Brain Res; 2008 Feb; 1195():50-5. PubMed ID: 18201687
[TBL] [Abstract][Full Text] [Related]
18. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex.
Yoshino T; Nisijima K; Shioda K; Yui K; Katoh S
Neurosci Lett; 2004 Jun; 364(1):16-21. PubMed ID: 15193747
[TBL] [Abstract][Full Text] [Related]
19. Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised.
Sanger GJ; Tuladhar BR; Brown J; Aziz E; Sivakumar D; Furness JB
Auton Autacoid Pharmacol; 2007 Apr; 27(2):105-11. PubMed ID: 17391280
[TBL] [Abstract][Full Text] [Related]
20. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
Di Pietro NC; Seamans JK
Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
